Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader

被引:17
作者
Zhu, Cheng-Liang [2 ,4 ,7 ]
Luo, Xiaomin [1 ]
Tian, Tian [3 ]
Rao, Zijian [2 ]
Wang, Hanlin [10 ]
Zhou, Zhesheng [2 ]
Mi, Tian [5 ]
Chen, Danni [2 ]
Xu, Yongjin [9 ]
Wu, Yizhe
Che, Jinxin [3 ]
Zhou, Yubo [1 ,5 ,6 ]
Li, Jia [1 ,5 ,6 ]
Dong, Xiaowu [3 ,7 ,8 ]
机构
[1] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[2] Zhejiang Univ, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[4] Ctr Drug Safety Evaluat & Res ZJU, Hangzhou 310058, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan Tsuihang New Di 528400, Guangdon, Peoples R China
[7] Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310016, Peoples R China
[8] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
[9] Canc Hosp Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc, Hangzhou 310005, Peoples R China
[10] Fudan Univ, Sch Pharm, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT; Protein kinase B; PROTAC; Chemical degrader; Rational design; MANTLE CELL LYMPHOMA; BIOLOGICAL EVALUATION; PATHWAY; DEGRADATION; INHIBITION; DERIVATIVES; BTK; IBRUTINIB; MK-2206; TARGET;
D O I
10.1016/j.ejmech.2022.114459
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AKT and associated signaling pathways have been recognized as promising therapeutic targets for decades, and growing evidence indicates that inhibition or degradation of cellular AKT are viable strategies to treat cancer. Guided by an in silico modeling approach for rational linker design and based on our previous work in this field, we herein efficiently synthesized a small group of cereblon-recruiting AKT PROTAC molecules and identified a highly potent AKT degrader B4. Compared to the existing AKT degraders, B4 has a structurally unique AKT targeting warhead derived from the pyrazole-furan conjugated piperidine derivatives. It induces selective degradation of all three isoforms of AKT and exhibits efficacious anti-proliferation against several human hematological cancers. Notably, B4 demonstrates potent inhibition of AKT downstream signaling superior to its parental inhibitor. Together with its active analogs, B4 expands the arsenal of AKT chemical degraders as a valuable probe to uncover AKTs new functions and as a potential drug candidate to treat cancer.
引用
收藏
页数:15
相关论文
共 71 条
  • [11] The Akt/PKB pathway: molecular target for cancer drug discovery
    Cheng, JQ
    Lindsley, CW
    Cheng, GZ
    Yang, H
    Nicosia, SV
    [J]. ONCOGENE, 2005, 24 (50) : 7482 - 7492
  • [12] Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer
    Chia, S.
    Gandhi, S.
    Joy, A. A.
    Edwards, S.
    Gorr, M.
    Hopkins, S.
    Kondejewski, J.
    Ayoub, J. P.
    Califaretti, N.
    Rayson, D.
    Dent, S. F.
    [J]. CURRENT ONCOLOGY, 2015, 22 (01) : 33 - 48
  • [13] Impact of linker length on the activity of PROTACs
    Cyrus, Kedra
    Wehenkel, Marie
    Choi, Eun-Young
    Han, Hyeong-Jun
    Lee, Hyosung
    Swanson, Hollie
    Kim, Kyung-Bo
    [J]. MOLECULAR BIOSYSTEMS, 2011, 7 (02) : 359 - 364
  • [14] Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
    Dal Col, Jessica
    Zancai, Paola
    Terrin, Liliana
    Guidoboni, Massimo
    Ponzoni, Maurilio
    Pavan, Alessandro
    Spina, Michele
    Bergamin, Stefano
    Rizzo, Silvana
    Tirelli, Umberto
    De Rossi, Anita
    Doglioni, Claudio
    Dolcetti, Riccardo
    [J]. BLOOD, 2008, 111 (10) : 5142 - 5151
  • [15] Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design
    Dong, Xiaowu
    Zhan, Wenhu
    Zhao, Mengting
    Che, Jinxin
    Dai, Xiaoyang
    Wu, Yizhe
    Xu, Lei
    Zhou, Yubo
    Zhao, Yanmei
    Tian, Tian
    Chen, Gang
    Jin, Zegao
    Li, Jia
    Shao, Yanfei
    He, Qiaojun
    Yang, Bo
    Weng, Qinjie
    Hu, Yongzhou
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (15) : 7264 - 7288
  • [16] Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors
    Dong, Xiaowu
    Zhou, Xinglu
    Jing, Hui
    Chen, Jianzhong
    Liu, Tao
    Yang, Bo
    He, Qiaojun
    Hu, Yongzhou
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (12) : 5949 - 5958
  • [17] Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies
    Drummond, Michael L.
    Henry, Andrew
    Li, Huifang
    Williams, Christopher, I
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2020, 60 (10) : 5234 - 5254
  • [18] In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
    Drummond, Michael L.
    Williams, Christopher I.
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2019, 59 (04) : 1634 - 1644
  • [19] Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
    Dumble, Melissa
    Crouthamel, Ming-Chih
    Zhang, Shu-Yun
    Schaber, Michael
    Levy, Dana
    Robell, Kimberly
    Liu, Qi
    Figueroa, David J.
    Minthorn, Elisabeth A.
    Seefeld, Mark A.
    Rouse, Meagan B.
    Rabindran, Sridhar K.
    Heerding, Dirk A.
    Kumar, Rakesh
    [J]. PLOS ONE, 2014, 9 (06):
  • [20] Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
    Erdmann, Tabea
    Klener, Pavel
    Lynch, James T.
    Grau, Michael
    Vockova, Petra
    Molinsky, Jan
    Tuskova, Diana
    Hudson, Kevin
    Polanska, Urszula M.
    Grondine, Michael
    Mayo, Michele
    Dai, Beiying
    Pfeifer, Matthias
    Erdmann, Kristian
    Schwammbach, Daniela
    Zapukhlyak, Myroslav
    Staiger, Annette M.
    Ott, German
    Berdel, Wolfgang E.
    Davies, Barry R.
    Cruzalegui, Francisco
    Trneny, Marek
    Lenz, Peter
    Barry, Simon T.
    Lenz, Georg
    [J]. BLOOD, 2017, 130 (03) : 310 - 322